Asset profile
VG-3927
Small molecule
Evidence outlook · lead readout
NCT06343636 · Healthy, Alzheimer Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06343636: The healthy-volunteer part of this trial randomly assigned participants to VG-3927 or a matching placebo under double-blind conditions, which is a real controlled design, but the Alzheimer's disease group received a single open-label dose with no comparator. As an early dose-escalation safety study with no results posted yet, it cannot show whether the drug produces any clinical benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.